
IGC Stock Forecast & Price Target
IGC Analyst Ratings
Bulls say
IGC Pharma is a clinical-stage pharmaceutical company with a positive outlook on its stock due to upcoming milestones, strong enrollment rates in its CALMA trial for IGC-AD1, reported positive interim results, and a focus on developing novel therapies for Alzheimer's disease. Additionally, the company recently reported strong fiscal Q1 2026 results and has a current valuation that represents significant upside potential. Risks to achieving their $5.25 price target include balance sheet/liquidity risks and potential competition in the market.
Bears say
IGC Pharma is a clinical-stage drug development company with a focus on Alzheimer's disease. While their investigational drug assets show potential in suppressing key hallmarks of Alzheimer's, there are significant risks involved including balance sheet/liquidity concerns, failure to gain regulatory approvals, and strong competition in the market. Additionally, the company has minimal revenue and a recent change in their fiscal year could impact their financials. However, if positive data is released and the Phase 2 CALMA trial is completed successfully, there is potential for high rewards due to the large and growing market for Alzheimer's treatments.
This aggregate rating is based on analysts' research of India Globalization Capital and is not a guaranteed prediction by Public.com or investment advice.
IGC Analyst Forecast & Price Prediction
Start investing in IGC
Order type
Buy in
Order amount
Est. shares
0 shares